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Abstract
Background: We previously reported the anti-estrogenic activity of the brown seaweed, Fucus vesiculosus. The
present study aimed to further investigate its anti-estrogenic modes of action and to assess other potentially
biologically relevant anti-tumorigenic effects in estrogen receptor (ER)-dependent and -independent female
cancer cell lines.
Methods: The CALUX® assay was used to determine the effect of a F. vesiculosus extract (FVE) on activation
of the ER. Aromatase enzymatic activity was measured to determine the potential effect of FVE on estradiol
(E2) biosynthesis. Transcriptional activity profiling of 248 genes involved in cancer, immunity, hormonal regulation,
protein phosphorylation, transcription, metabolism, and cellular structure was conducted using the NanoString
nCounter® analysis system in FVE-treated breast, ovarian and endometrial cancer cell lines. The effects of FVE
on cell viability, morphology, membrane integrity, mitochondrial toxicity, induction of apoptotic and autophagic
markers, and cell signaling were also analyzed.
Results: In co-treatments with 12.5 pM (EC50) E2, FVE (2 %) reduced ER activation by 50 %, exhibiting potent ER
antagonistic effects. FVE inhibited aromatase activity in an in vitro assay (IC50 2.0 %). ER-dependent and -independent
cancer cell lines showed significantly decreased viability that correlated with increasing FVE concentrations and altered
morphological features suggestive of apoptosis and autophagy. Expression of genes that were significantly altered by FVE
(p < 0.05) revealed predominantly apoptotic, autophagic and kinase signaling pathways. FVE also effectively inhibited the
phosphorylation of Akt, resulting in reduced mTORC1 activities to stimulate autophagy in cells. Concentration-dependent
cleavage of PARP and induction of caspase-3 and -7 activities were observed in MDA-MB-231 cells supporting a role for
FVE in the promotion of apoptosis.
Conclusions: Our study provides new insights into the anti-estrogenic activity of F. vesiculosus. Moreover, the induction of
autophagy and apoptosis on breast, endometrial and ovarian cancer cell lines suggests additional anti-tumorigenic
actions of FVE that are independent of ER status in female cancers.
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Background
Brown seaweeds such as Fucus vesiculosus are widely
consumed by the public due to their potential anti-cancer
activities warranting the need for further studies to cha-
racterize their biological actions. We previously reported
anti-estrogenic properties of F. vesiculosus in human and
animal studies [1]. Specifically, in a small case study, F.
vesiculosus administered to pre-menopausal women with
endometriosis led to a reduction in circulating estradiol
(E2) levels, an increase in the length of the menstrual
cycle, and diminished symptoms of hypermenorrhea and
dysmenorrhea [1]. Anti-estrogenic action was further dem-
onstrated where dosing with a F. vesiculosus extract (FVE)
in primary human luteinized granulosa cell cultures led to
marked reductions in E2 levels [2]. Rats fed F. vesiculosus
exhibited increased estrous cycle lengths and reduced
serum E2. FVE also exerted inhibitory effects on the
binding of E2 to estrogen receptor (ER)α and ERβ [2].
To further explore the anti-estrogenic activity of F.
vesiculosus, the effects of FVE were tested on the activa-
tion of the ER and inhibition of aromatase enzymatic ac-
tivity. We also investigated other modes of action of
FVE biologically relevant to cancer initiation and pro-
gression in breast, endometrial and ovarian cancer cell
lines. Fucoidan is a major component of F. vesiculosus
and other brown seaweeds and exhibits anti-tumor
and anti-metastatic activities in numerous cancers [3].
Therefore, we included fucoidan purified from F. vesi-
culosus in our in vitro studies to compare its effects
with those of FVE.
Methods
F. vesiculosus aqueous extract preparation
Atlantic F. vesiculosus (Maine Coast Sea Vegetables, Inc.,
Franklin, ME) was ground into a fine powder, mixed with
deionized water (5 g into 100 mL) and stirred 2 h at room
temperature. The insoluble material was removed by
centrifugation; the supernatant (70 mL) was sterilized by
filtration through a 0.2 μM filter and stored in 1-mL
aliquots at −20 °C. This constitutes the 100 % v/v stock
extract. For all experiments, treatment concentrations of
the extract are expressed as the % v/v. For example, a 100-
fold dilution in cell culture medium is expressed as 1 %.
Four aliquots were completely dried under a vacuum
using a SpeedVac evaporator overnight yielding 35 mg of
solid residue per mL of extract. In total, the 70-mL extract
contained 2.45 g of water-soluble material extracted from
5 g of starting plant powder.
Antibodies and reagents
Antibodies to Akt, phospho-Akt (Ser473), phospho-Akt
(Thr308), beclin-1, phospho-Beclin-1 (Ser15), phospho-
PI3Kinase p85(Tyr458)/p55 (Tyr199), phospho-4E-BP1
(Thr37/46), p70S6K, phospho-p70S6K(Thr389), LC3B,
poly(ADP-ribose) polymerase (PARP), cleaved PARP
(D214) and anti-rabbit IgG HRP-linked antibody were
purchased from Cell Signaling Technology (Beverly,
MA, USA). Mouse monoclonal β-Actin antibody and
crude fucoidan from F. vesiculosus were obtained from
Sigma-Aldrich (St Louis, MO, USA). DMEM (Dulbecco’s
Modification of Eagle’s Medium) with 4.5 g/L glucose, L-
glutamine and sodium pyruvate, trypsin-EDTA, penicillin-
streptomycin-amphotericin B solution (50X), fetal bovine
serum (FBS), phosphate buffer solution (PBS), and PBS
with Tween 20 (PBST) were purchased from Life Tech-
nologies (Waltham, MA, USA).
Estrogenic activity of FVE measured by a reporter assay
The effect of FVE on E2 signaling was investigated using a
chemically activated luciferase reporter (CALUX® assay) for
ERα and ERβ. The ER activity reporter, T47D-KBluc cell
line, was purchased from ATCC (Manassas, VA). This
CALUX® assay cell line is permanently transfected with a
plasmid reporter construct expressing luciferase under con-
trol of a promoter region containing several repeats of the
cognate responsive element for ER. Cells grown in medium
depleted of steroids (charcoal filtered FBS (5 %) in DMEM
without Phenol-red) for 7 days to minimize background ac-
tivity were seeded in opaque 96-well plates and allowed to
attach overnight. Medium containing 0 to 25 pM E2 as the
calibration standard, or FVE (0 to 2 %) either alone or in
co-treatments with 12.5 pM E2, was added to the wells in
triplicates. Fucoidan was also tested in this assay at a range
of concentrations (0 to 0.50 mg/mL). After a 24-h incuba-
tion, cells were lysed and luciferase activity was measured
with a microplate luminometer using the Promega Flash
Luciferase Assay kit (Madison, WI). A clear 96-well
plate was seeded and treated identically and was used
to normalize the luminescence raw data for possible
cell number variations (measured with the MTT assay)
due to the 24-h exposure to the treatments. Estrogenic
activity was expressed as pM E2 equivalents.
Effects of FVE on aromatase activity
Aromatase activity was measured using the CYP19/MFC
High Throughput Inhibitor Screening Kit (Discovery
Labware, Inc. Wolburn, MA) according to the manufac-
turer’s instructions. Briefly, recombinant human CYP19
enzymatic hydrolysis of the fluorescent substrate, 7-
methoxy-4-trifluoromethyl coumarin, was used to measure
aromatase activity in vitro in a 96-well plate. Ketoconazole
was used as the positive marker of aromatase inhibition.
FVE was tested in this assay at a 0 to 2 % range of
concentrations.
Cell lines and culture conditions
Human MDA-MB-231 and MCF-7 breast cancer cells were
kindly provided by Dr. Samant (University of Alabama,
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Birmingham, AL) and the breast carcinoma (T47D), ovar-
ian carcinoma (OVCAR-3 and Caov-3), uterine endomet-
rium carcinoma (HEC-1-B, RL95-2 and AN3CA) and
uterine sarcoma (MES-SA) cell lines were obtained from
ATCC. The MDA-MB-231/GFP-LC3 stable cell line was a
gift from Dr. Xu [4] (University of Alabama, Birmingham,
AL). Cell lines were maintained in their respective ATCC
recommended media at 37 °C, in 100 % humidity and
5 % CO2.
Effects of FVE on cell viability
The effects of FVE on the viability of all nine cell lines
were analyzed using the MTT assay (Promega Corp.
Madison, WI). Specifically, cells were seeded at 105 per
well in 12-well plates and after overnight attachment,
FVE (0 to 2 %) was added to the medium in triplicate
wells. After 72 h, MTT dye was added to the medium,
incubated one hr at 37 °C. The formazan crystals were
dissolved in Solubilization Solution/Stop Mix and the
OD 570 nm was used as a measurement of viable cell
number.
Toxicity assessment
The Mitochondrial ToxGlo™ Assay (Life Technologies,
Carlsbad, CA) was used to assess cell toxicity, which relies
on biomarkers associated with changes in cell membrane
integrity and cellular ATP levels. Cell membrane permeabil-
ity in necrotic cells is indicated by the presence of specific
protease activity, using the fluorescent proteolytic product
of the peptide substrate (bis-AAF-R110). Digitonin is a
positive marker for cellular membrane permeabilization.
Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) is a
positive marker of mitochondrial toxicity.
Gene expression profiling
As an initial screening tool, transcript levels were measured
(nCounter® Analysis System, (NanoString Technologies,
Seattle, WA) in a panel of 248 genes involved in cancer,
immunity, hormonal regulation, protein phosphoryl-
ation, transcription, metabolism, and cellular structure
(Additional file 1: Table S1) in a subset of 6 cell lines
(MCF-7, T47D, MDA-MB-231, RL95, HEC-1-B, RL95-2
and OVCAR-3). Cells were treated with FVE (0, 0.25 and
1.0 %, up to 4 h) and mRNA transcript levels were mea-
sured using total RNA that was purified using the Qiagen
RNeasy Mini Kit and quantified using a BioTek Take-3
UV spectrophotometer. The geometric mean of six house-
keeping genes (TUBB, G6DP, GAPDH, POLR2A, RPL19
and TBP) was used as the reference for normalization of
measured mRNA levels. To filter out genes expressed at
low background levels, we removed those with expression
levels below 4 in all samples after normalization (70
counts in the raw data). For the remaining genes, a
two-way ANOVA model with cell line effect and
treatment dose effect was fitted to the normalized and
logarithm-transformed expression data for each gene.
The permutation-based F-test was used to identify
genes differentially expressed between treatment doses.
Due to the screening characteristics, we used a nominal
p-value of 0.05 as significance threshold. Analyses were
conducted in R, version 3.0.0.
Assessment of FVE on apoptosis and autophagy with
pan-caspase and autophagy inhibitors
The relative contribution of apoptosis and autophagy
to the reduced viability of the cancer cells exposed to
FVE was examined using co-treatment with specific
inhibitors. The pan-caspase inhibitor, Z-VAD (OMe)-
FMK (VAD, 60 μM) and the autophagy inhibitor, 3-
methyladenine (3-MA, 8 mM; Cayman Chemicals,
Ann Arbor, MI) were used in co-treatments with 1 %
FVE -for 72 h.
Caspase activity assay
Caspase activity was determined using the EnzChek
Caspase-3 Assay Kit #1 (Molecular Probes, Grand Island,
NY). Briefly, estrogen-dependent MCF-7 and estrogen-
independent MDA-MB-231 breast cancer cells were incu-
bated 2 h with 1 % FVE. Cells were collected after trypsin
digestion, washed in PBS, and lysed in 1x lysis buffer by
freeze and thaw. After centrifugation (5,000 x g, 5 min),
the supernatant containing 100 μg protein was incubated
with substrate (Z-DEVD-AMC, 25 °C, 30 min) or pre-
incubated with caspase-3/7 inhibitor (Ac-DEVD-CHO)
(10 min) before addition of substrate (Z-DEVD-AMC).
Released AMC fluorescence was measured with a micro-
plate reader (Synergy-H1) at excitation/emission 342/
441 nm and the net change of fluorescence was calculated
by subtraction of the fluorescence of the sample pre-
incubated with the inhibitor. Caspase-3/7 activities were
determined by direct comparison to the level in the un-
treated control cells. For caspase inhibitor treatments, cells
were pretreated with a synthetic cell-permeable pan-
caspase inhibitor (Z-VAD (OMe)-FMK, 10 mM, 30 min)
before the addition of 1 % FVE and incubated for an add-
itional 2 h.
Fluorescence microscopy
MDA-MB-231 cells/GFP-LC3 were grown to 60 % conflu-
ence in six-well plates with cover slides in DMEM supple-
mented with 10 % FBS. Cells were treated with FVE (0 to
2 %, 16 h) and fixed in 4 % neutral paraformaldehyde in
PBS for 15 min at room temperature and washed 3 times
in PBS. Slides were mounted with antifade medium Dapi
Fluoromount-G (Southern Biotech, Birmingham, AL) and
the GFP-LC3 staining was observed using a fluorescence
microscope.
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Western blots
Immunoblots were used to study the effects of FVE on
phosphorylation and activation of kinases in the PI3K-
Akt-mTOR pathway. Cells grown in 6-well plates were
treated with FVE (0 to 2 %, up to 8 h), then lysed in RIPA
buffer supplemented with a cocktail of protease and phos-
phatase inhibitors. After the addition of 2X Laemmli load-
ing solution containing 10 % β-mercaptoethanol, cell
lysates were sonicated 5 s and denatured at 100 °C for
5 min. SDS-Page Gels (Mini-Protean TGX Precast Gels,
Any kD, BioRad, Hercules, CA) were loaded with 30 μg of
sample per lane, run at 200 V for 40 min and transferred
to PVDF membranes using the rapid semi-dry Trans-Blot
Turbo Transfer System (BioRad, Hercules, CA). Blots
were blocked in 5 % non-fat dry milk at 37 °C for 30 min
followed by overnight incubation at 8 °C with primary
antibodies in blocking buffer. Secondary antibodies conju-
gated to HRP were imaged by enhanced chemolumines-
cence on a ChemiDoc MP imaging system (BioRad) and
analyzed using BioRad’s Image Lab software. Blots were
re-probed with different antibodies after treatment with
Restore™ Plus Western Blot Stripping Buffer (Thermo
Fisher Scientific, Rockford, IL).
Statistical analyses
Experimental data were analyzed by the Student’s t-test.
Data are shown as means ± S. E. of values obtained from
triplicate or quadruplicate experiments. A cut-off value
of p < 0.05 was used to indicate statistical significance.
Results and discussion
FVE inhibits ER activation and aromatase activity
We previously reported the anti-estrogenic activity of F.
vesiculosus, and that one mode of action was competitive
inhibition of E2 binding to the ER [1, 2]. However, the
effect of the extract upon ER activation was never tested.
Here, using the Calux assay, we found that in cells co-
treated with E2 at 12.5 pM (EC50), FVE significantly re-
duced the activation of the luciferase reporter up to
50 % (p < 0.001) (Fig. 1a), suggesting that FVE is a potent
antagonist of ER activation by E2. Moreover, in vitro en-
zymatic activity of aromatase was inhibited by FVE with
an IC50 of 2 % (Fig. 1b). However, fucoidan did not alter
ER activation or aromatase activity (data not shown)
even at concentrations in excess of the 10 % of dry
weight reported for F. vesiculosus [5]. Inhibition of aro-
matase enzymatic activity by FVE provides a potential
mechanism for the decreased serum E2 levels that we
previously reported following consumption of F. vesicu-
losus [1]. The dual actions of an antagonistic effect on
the activation of the ER by circulating E2, together with
reduced levels of E2 synthesis through aromatase inhib-
ition, suggests that F. vesiculosus may play a protective
role in the initiation and progression of estrogen-
dependent cancers.
Reduced viability in FVE-treated cancer cell lines
As measured by the MTT assay of mitochondrial activ-
ity, treatment with FVE showed reduced cell viability
after a 3-day period in most cancer cell lines tested, in a
dose-dependent fashion, though sensitivity was highly
variable between cell lines (Fig. 2a-c). FVE exerted the
greatest reduction in cell viability in the HEC-1-B and
RL95-2 endometrial cells (Fig. 2b); whereas, there was
no significant effect on cell viability in the Caov-3 ovar-
ian carcinoma cells (Fig. 2c). The cell line-specific sensi-
tivity suggests that FVE is not toxic at the concentration
range in our experiments, but instead induces cell death
through modulated pathways. These observations also
support our previous reports of the non-toxic effects of
a
b
Fig. 1 Anti-estrogenic effects of FVE through inhibition of estrogen
receptor (ER) activation and aromatase activity. a In co-treatment
with E2 (EC50, 12 pM), FVE inhibited ER activation with an IC50 of
2 %, but exerted no effect on ER activity alone. b FVE inhibited
aromatase enzymatic activity in vitro with an IC50 of 2 %.
*p < 0.05; **p < 0.001
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F. vesiculosus in vivo [1, 2]. The toxicity of FVE was fur-
ther studied in a dual assay of mitochondrial production
of ATP and of cell membrane permeability. Treatment
with FVE at the same concentrations (up to 2 %) shown
to reduce cell viability in MCF-7 cells did not produce
toxic effects when compared to the effects of the positive
markers for mitochondrial toxicity (CCCP) and for
membrane permeabilization (digitonin), indicating that
there was no necrotic effect due to primary toxicity
(Additional file 1: Figure S1 A-C). Results were similar
for all cell lines tested (data not shown). In the course of
the cell proliferation experiments, we observed morpho-
logical changes within the cells, featuring predominantly
large cytoplasmic vesicles after 72 h of treatment with
1 % FVE. Additional file 1: Figure S2 shows typical
morphology alterations in six representative cell lines.
FVE treatment alters expression of genes involved in
apoptosis, autophagy and cell signaling
Gene expression profiling studies revealed that breast,
endometrial and ovarian cells treated with FVE com-
pared to untreated controls exhibited differentially
altered transcript levels (p < 0.05) in genes primarily
involved in apoptosis (APAF1, CASP6, FANCG,
MED1, XIAP), autophagy (ATG10, GABARAP) and in
genes in signaling pathways modulated by protein ki-
nases (BRAF, MAP3K14, PIK3R4, PRKAA1, PRKACB,
PRKAR1A, PRKAR2A) (Additional file 1: Figure S3).
These results suggested that the reduced cell viability
by FVE was through induction of apoptosis and/or au-
tophagy warranting further investigation of these
mechanisms. Morphological observations of the can-
cer cells exposed to FVE also supported initiation of
cell death by apoptosis and/or autophagy (Additional
file 1: Figure S3).
FVE-induced reduction of cancer cell viability is
attenuated by specific inhibitors of apoptosis and
autophagy
The contributions of apoptosis and autophagy to the
reduced viability of the cancer cells exposed to FVE were
examined using co-treatments with VAD, the pan-
caspase inhibitor, and 3-MA, the autophagy inhibitor, in
MCF-7, MDA-MB-231, HEC-1-B, MES-SA, AN3-CA,
OVCAR-3 and Caov-3 cells. We found that co-
treatment with VAD reversed the actions of FVE on cell
viability in MDA-MB-231, AN3-CA and OVCAR cells
(Additional file 1: Figure S4). To further explore the
contribution of apoptosis in the reduction of cell viabil-
ity by FVE, we measured caspase activity in MCF-7 and
MDA-MB-231 cells (Fig. 3a and b) as representative of
VAD-unresponsive and -responsive cell lines, respect-
ively. FVE did not affect caspase activity in MCF-7 cells
(Fig. 3a), which is consistent with the lack of caspase-3
expression in MCF-7 cells [6]. However, caspase activity
was increased in FVE-treated MDA-MB-231 cells, and
the addition of VAD reduced this activity (Fig. 3b). PARP
cleavage by caspase-3 serves as one hallmark of apop-
tosis and caspase activation [7]. Thus, we used Western
blotting with an antibody specific for cleaved PARP
which showed no apparent PARP cleavage in MCF-7
cells (Fig. 3c), but increased PARP cleavage in FVE-
treated MDA-MB-231 cells (Fig. 3d) in a concentration-
dependent manner (Additional file 1: Figure S5). These
studies suggest that apoptosis is not the primary mech-
anism in the cell killing effect of FVE on MCF-7 cells,
ba c
Fig. 2 Cell viability as measured by the MTT assay in (a) breast (MCF-7, T47D, MDA-MB-231), (b) uterine (HEC-1-B, RL95-2, MES-SA, AN3-CA), and
(c) ovarian (OVCAR-3, Caov-3) cancer cell lines
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but apoptosis does play a role in cell death in MDA-
MB-231 cells.
When cells were co-treated with FVE and 3-MA, the ef-
fects of FVE on cell viability were diminished in all cell lines
tested, except in Caov-3 cells which were not responsive to
FVE, indicating that autophagy plays a predominant role in
FVE-induced cell death (Additional file 1: Figure S4). These
results are consistent with the report by Cheng et. al. that
showed the reversal of autophagy by 3-MA in MCF-7 and
MDA-MB-231 cell lines [8].
FVE induces autophagy in MDA-MB-231 cells
FVE-induced autophagy was further demonstrated using
MDA-MB-231/GFP-light-chain 3 (LC3), a stable cell line
expressing green fluorescent protein (GFP)-tagged LC3
(Fig. 4a). During the autophagic process, LC3 is concen-
trated in autophagic vesicles (autophagosomes) forming
cytosolic punctate fluorescence, which serves as an indi-
cator of autophagy [9, 10]. Overnight treatment with
FVE at concentrations as low as 0.1 % led to discrete
vesicular structures (GFP puncta, Fig. 4a).
Inhibition of PI3K/Akt/mTOR signaling by FVE
It is well established that PI3K is associated with numerous
cellular processes including cell growth, proliferation, differ-
entiation, motility, survival and intracellular trafficking.
Many of these functions relate to the ability of class I PI3-
kinases to activate Akt in the PI3K/Akt/mTOR pathway
[11]. mTOR is a critical effector of PI3K signaling in many
human cancers [12], and disruption of the pathway results
in apoptotic cell death [13, 14]. Moreover, autophagy is
tightly controlled by the mTOR-dependent signal transduc-
tion pathway, and inhibition of mTOR activity promotes
autophagy [15, 16].
To further explore these mechanisms, we studied the
effects of FVE on phosphorylation and activation of ki-
nases in the PI3K-Akt-mTOR pathway in MCF-7 and
MDA-MB-231 cells. Western blot data are presented in
Fig. 4 as representative ER-positive and ER-negative cell
lines and their respective quantifications are shown in
Additional file 1: Figure S6 and S7. FVE significantly re-
duced Akt phosphorylation at Ser473 and Thr308, with-
out changing the levels of total Akt in MCF-7 (Fig. 4b1)
and MDA-MB-231 (Fig. 4c1) cells. The effects were
dose-dependent and were achieved in less than 2 h. Lon-
ger treatments (4 and 8 h) showed no further decrease
of p-Akt-Ser/Thr in MCF-7 cells, but in MDA-MB-231
cells at 8 h, there was a more marked decrease of p-Akt-
Ser473. Consistent with the inactivation of Akt, the
phosphorylation of the p85 regulatory subunit of PI3K
was decreased with FVE treatment in MCF-7 and MDA-
MB-231 cells (Fig. 4b2 and c2). We also observed that
a b
c d
Fig. 3 Effects of FVE on apoptosis in (a) MCF-7 cells and (b) MDA-MB-231 cells with the pan-caspase inhibitor, VAD. c Effects of FVE on PARP
cleavage in MCF-7 and (d) MDA-MB-231 cells. The antibody does not recognize full length PARP1 or other PARP isoforms. *p <0.05; **p < 0.01
compared to control
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FVE-induced inhibition of Akt phosphorylation resulted
in decreased mTOR complex activity as evidenced by a
significant reduction in levels of the mTORC1 effectors,
p-4E-BP1 and p-p70S6K (Fig. 4b2 and c2). The effect of
FVE on the reduction of p-Akt-Ser/Thr was observed in
T47D, OVCAR-3, HEC-1-B, RL95-2, AN3-CA and
MES-SA cell lines (data not shown), but not in Caov-3
cells where there were no detectable p-Akt-Ser/Thr
levels. This is consistent with the lack of Akt activity in
Caov-3 cells [17] and may explain the ineffectiveness of
FVE on reducing Caov-3 cell viability. These results sug-
gest that FVE is a mediator of autophagic cell death
through reduced phosphorylation of key components of
the PI3K/Akt/mTOR pathway.
FVE promotes conversion of LC3B-I to LC3B-II and
increases phosphor-Beclin 1
To further explore the effects of FVE treatment on au-
tophagy, we examined the autophagic marker, LC3B.
We observed significant conversion of LC3B-I to the
smaller form, LC3B-II (Fig. 4b3, c3), which was con-
centration- and time-dependent. LC3B-I conversion to
LC3B-II through ubiquitination allows LC3B associ-
ation with autophagic vesicles. The presence of LC3B
in autophagosomes, and the conversion of LC3B-I to
LC3B-II are used as indicators of autophagy [18–20].
Increased levels of phospho-Beclin 1 also were seen
after treatment with FVE (Fig. 4b3, c3). The balance
between apoptosis and autophagy is regulated by
a
b1
c1
b2
c2
b3
c3
Fig. 4 FVE-induced autophagy. a Accumulation of GFP-LC3 punctate vesicles in MDA-MB-231 cells. (b1 and c1) FVE reduced Akt phosphorylation
at Ser473 and Thr308 in MCF-7 and MDA-MB-231 cells. (b2 and c2) FVE decreased PI3K, 4-EB-P1 and p70S6K phosphorylation in MCF-7 and MDA-
MB-231 cells. (b3 and c3) FVE promoted accumulation of phospho-Beclin 1 and LC3B II in MCF-7 and MDA-MB-231 cells
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Beclin 1 and is dependent on the dose of the stimulus
[21, 22]. The higher levels of phospho-Beclin 1 in-
duced by FVE further suggest that aberrant autophagy
is the predominant process involved in its action in
promoting cell death.
Phosphorylation of Akt is not effected by fucoidan
In contrast to what we observed with FVE (Fig. 4b1, c1),
fucoidan did not reduce p-Akt at Ser473 or Thr308 levels
(Additional file 1: Figure S8). The lack of inactivation of
Akt and no apparent effects on proliferation suggest that
fucoidan is not the active compound responsible for the
inhibition of PI3K/Akt/mTOR signaling by FVE in the cell
lines tested.
Conclusions
Our results provide further evidence of the anti-estrogenic
activity exerted by FVE that involves inhibition of ER acti-
vation by E2, and inhibition of E2 synthesis. This activity
suggests that FVE may provide a beneficial protective ef-
fect against estrogen-dependent breast, endometrial and
ovarian cancers. Moreover, the reduced viability of ER-
positive and -negative cancer cell lines treated with FVE
through inactivation of the PI3K/Akt/mTOR pathway
suggests that FVE may be useful in the treatment of some
breast, endometrial and ovarian cancers regardless of ER
status. MDA-MB-231 breast, HEC-1B endometrial and
OVCAR-3 ovarian cells do not express the ER, but were
sensitive to FVE; HEC-1B endometrial carcinoma cells
were the most sensitive to FVE. Endometrial cancers are
often aggressive, and therapeutic options are limited and
sometimes ineffective. Therefore, the identification of new
therapeutic agents is highly desirable. Studies to further
characterize the chemoprotective and anti-tumorigenic
actions of FVE are currently underway.
Additional file
Additional file 1: Table S1. 248 genes analyzed for expression profiling
(Nanostring™ nCounter®) and 6 housekeeping reference genes. Figure S1.
Assays of toxicity. (A) FVE effects on membrane permeability and
mitochondrial ATP. (B) Digitonin used as positive control for primary
necrosis. (C) CCCP used as positive control for mitochondrial toxicity.
Figure S2. Morphological alterations. (A) FVE-untreated and (B)
-treated cells with 1.0 % FVE, 48 hr. Figure S3. Heatmap of
differential mRNA expression following FVE treatment at 0.25 % and
1.0 % (4 hr) in MCF-7, T47D, MDA-MB-231, HEC-1-B, RL95-2 and
OVCAR-3 cell lines; significance level, p <0.05. Figure S4. Treatment
of MCF-7, MDA-MB-231, HEC-1-B, MES-SA, AN3-CA, OVCAR-3 and
Caov-3 cells with apoptosis (VAD) and autophagy (3MA) inhibitors;
*indicates significant difference with FVE without inhibitor (p <0.05).
Figure S5. FVE-induced apoptosis via caspase3/7-mediated PARP
cleavage in MDA-MB-231 cells; *p <0.05, **p <0.01 compared to
controls. Figure S6. FVE down-regulates PI3K/Akt/mTOR signaling in
MCF-7 cells. (A) FVE reduced Akt phosphorylation at Ser473 and
Thr308, (B) decreased PI3K, 4-EB-P1 and p70S6K phosphorylation, and
(C) promoted accumulation of phospho-Beclin-1 and LC3B II. Data are
from >3 independent Western blots normalized by β-actin levels;
*p <0.05, **p <0.01 compared to controls. Figure S7. FVE down-
regulates PI3K/Akt/mTOR signaling in MDA-MB-231 cells. (A) FVE
reduced Akt phosphorylation at Ser473 and Thr308, (B) decreased
PI3K, 4-EB-P1 and p70S6K phosphorylation, and (C) promoted phospho-
Beclin-1 and LC3B II accumulation. Data are from >3 independent Western
blots normalized by β-actin levels; *p <0.05, **p < 0.01 compared to
controls. Figure S8. Fucoidan up-regulates phosphor-Akt. (A) Fucoidan
increased Akt phosphorylation at Ser473 in MCF-7 cells in a concentration-
dependent manner; no change in Akt phosphorylation at Thr308. (B)
Fucoidan increased Akt phosphorylation at Ser473 in MDA-MB-231 cells in a
concentration- and time-dependent manner; no changes observed in Akt
phosphorylation at Thr308. (PDF 11350 kb)
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